Search

Displaying results 2771 - 2780 of 7059 in total
  1. Drug

    Cromoglicate lisetil

    go.drugbank.com/drugs/DB21297
    Experimental

    Cromoglicate lisetil is a small molecule drug. Cromoglicate lisetil has a monoisotopic molecular weight of 652.23 Da.

  2. Drug

    Iobutoic acid

    go.drugbank.com/drugs/DB21443
    Experimental

    Iobutoic acid is a small molecule drug. Iobutoic acid has a monoisotopic molecular weight of 670.82 Da.

  3. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G.

  4. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin D immune FAB2 (equine), BOTULINUM NEUROTOXIN D IMMUNE FAB2, EQUINE
  5. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito. … The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease

    Synonyms: Yellow fever virus live antigen, A
  6. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

  7. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  8. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A2331] Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in the inhibition of DNA synthesis and cytotoxicity. … [A2332] Due to the rarity of these T-cell malignancies, nelarabine was first granted orphan drug status and a fast-track designation by the FDA to address the unmet therapeutic needs of these cancers.

    Synonyms: 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine
  9. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.

    Products: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML
  10. Drug

    Silanol

    go.drugbank.com/drugs/DB11343
    Approved

    Silanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and silicate mineralogy.